



Eurofins Announces AOAC and Afnor Certification for BACGene and BACSpec Listeria kits

4 July 2017

Eurofins Scientific (EUFI.PA), a global leader in bioanalytical testing, announces that its real-time PCR kits for *Listeria* testing, *BACGene Listeria*, as well as the *BACSpec Listeria* ELISA kit have received certification by AOAC and AFNOR.

Fast and efficient detection of food borne pathogens is the key factor for food testing laboratories in order to support their customers with the quality assurance of their products. Food producers expect their laboratories to work with methods that have been tested and recognized by international certification bodies. Eurofins' *BACGene Listeria* kits now entirely fulfill these requirements.

Classical cultural methods for bacteria are time-intensive and laborious. The use of efficient methods is becoming increasingly important for microbiological laboratories. Eurofins' PCR and ELISA kits for the detection of *Listeria* offer laboratories fast and reliable results.

BACGene Listeria Multiplex is the first true multiplex real-time PCR detection for *Listeria* spp. and *Listeria monocytogenes* in one single reaction, thus providing a better work and cost efficiency for microbiology laboratories. If just one target is of interest, the real-time PCR kits *BACGene Listeria monocytogenes* and *BACGene Listeria* spp. are alternatively available. All kits offer the fastest time-to-result and are certified for food and environmental samples by AFNOR Certification as an alternative method for *Listeria monocytogenes* and *Listeria* spp. according to EN ISO 16140 and by AOAC-Research Institute under the Performance Tested MethodsSM Program.

BACSpec Listeria is a fast, robust and cost effective ELISA kit to detect *Listeria* in various food and environmental samples. The kit is certified for food and environmental samples by AFNOR Certification as an alternative method for *Listeria* spp. according to EN ISO 16140 and by AOAC-Research Institute under the Performance Tested MethodsSM Program.

These kits enable microbiology laboratories to offer their customers state-of-the-art assays. The methods are specifically designed, validated and certified based on customer requirements. The certifications include MALDI-TOF as a confirmation method, thereby decreasing the overall analysis time.

The *Listeria* kits enhance Eurofins product portfolio for pathogen detection which already comprises the *BACGene Salmonella* spp. real-time kit (AOAC PTM and AFNOR certified) and the *BACSpec Salmonella* kit (AOAC certified). These products are available to customers who run microbiological laboratories.

For more information, please visit www.eurofins.com or contact:

Eurofins GeneScan GmbH
Dr. Nicholas Krohn
Phone: +49 761 5038 100
Email: NicholasKrohn@eurofins.com

Investor Relations
Eurofins Scientific
Phone: +32 2 766 1620

For inquiries about our products, please contact:

In North America: Eurofins Technologies North America: technologies.us@eurofins.com
In France: Eurofins Technologies France technologies.fr@eurofins.com
In Asia Pacific: Eurofins Technologies Singapore technologies.apac@eurofins.com
In Italy: Tecna technologies.it@eurofins.com
In the Rest of the World: Eurofins GeneScan technologies.de@eurofins.com

Notes for the editor:

Eurofins – a global leader in bio-analysis

Eurofins Scientific through its subsidiaries (hereinafter sometimes “Eurofins” or “the Group”) believes it is the world leader in food, environment and pharmaceutical products testing and that it is also one of the global independent market leaders in certain testing and laboratory services for agrosience, genomics, discovery pharmacology and for supporting clinical studies. In addition, Eurofins is one of the key emerging players in specialty clinical diagnostic testing in Europe and the USA. With over 28,000 staff in 310 laboratories across 39 countries, Eurofins offers a portfolio of over 130,000 analytical methods for evaluating the safety, identity, composition, authenticity, origin and purity of biological substances and products, as well as for innovative clinical diagnostic. The Group objective is to provide its customers with high-quality services, accurate results on time and expert advice by its highly qualified staff.

Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and the most comprehensive range of testing methods.

As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients' increasingly stringent quality and safety standards and the expanding demands of regulatory authorities around the world.

The shares of Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).

Important disclaimer:

This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgement of Eurofins Scientific' management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company's management as of the date of publication, but no guarantee can be made as to their validity.